Synergy Research Group Finishes 2014 Strong

Share Article

Milestones include new Ukraine Orange Paper, complete transparency and successful clinical trials

We are very proud of what we've achieved in 2014 and look forward to another great year in 2015.

Synergy Research Group is finishing 2014 with strong achievements, continued success and quality. The year was punctuated with the release of the first Ukraine Orange Paper, produced with the cooperation of the Ministry of Health from that country, a new interactive dashboard of all current projects and the implementation of advanced EDC functionality from Clinovo.

Synergy started 37 new studies in 2014, which involved 12,318 patients and 318 sites. It began work with six new sponsors. Of the studies conducted in 2014, 17 were full service, 11 were monitoring, six were medical writing, one was data management and biostatistics and one was regulatory consulting.

“In 2014, we have continued our drive to be a world-class clinical research organization,” said Igor Stefanov, CEO of Synergy Research Group. “We added new offerings that no-one else has done before, like our interactive dashboard that gives total transparency into our performance.”

The studies conducted by Synergy Research Group in 2014 included 14 oncology studies, five cardiology, three gastro and three infectious disease. Nineteen of the studies were Phase III, one was Phase I, two were Phase IV, four were Bioequivalence and nine were non-interventional.

Another milestone for 2014 was the first edition of the Orange Paper Ukraine. The report gives a comprehensive snapshot of the state of clinical affairs in the country and was produced from data that was obtained through the cooperation of the country’s Ministry of Health.

“Synergy Research Group continues to grow and to attract top talent, both in the company and the sites we work with,” Stefanov continued. “We are very proud of what we’ve achieved in 2014 and look forward to another great year in 2015.”

Russia boasts large patient populations across high-demand therapeutic areas such as oncology, infectious disease, and cardiovascular. Per-patient study costs are low in the region, despite having a large number of experienced researchers in multiple sites. Additionally, the per-patient spend on pharmaceuticals in the region is expected to more than double by 2016, growing to over four billion dollars annually.

Synergy Research Group leads the Russian market in full-service contract research. The company has senior management teams with deep domain expertise, as well as executives with experience working inside regulatory agencies who speed the approval processes.

About Synergy Research Group
Synergy Research Group, http://synergycro.ru/, is a full-service Contract Research Organization (CRO) founded in 2002 that delivers its Troika Promise of Speed, Cost and Quality to clients. Synergy provides a full range of CRO services to help global pharmaceutical and biotechnology companies conduct successful and cost-effective clinical trials. The company provides transparency, access and control to sponsors during the entire project through its cloud-based monitoring system. Synergy has locations in Moscow, Saint-Petersburg, Novosibirsk, Yekaterinburg, Perm, Krasnodar, Almaty and Astana (Kazakhstan) and Kyiv (Ukraine). The company's headquarters are in Moscow.

# # #

Share article on socal media or email:

View article via:

Pdf Print

Contact Author

Leslie Proctor
Springboard5 Marketing
(801) 208-1100
Email >
Visit website